Loading the session
Loading the session
Loading instrument
$17.01
+2.29%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:26 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: +18.7% (SPY −1.6%, XLV +13.5%). 3 months: −31.2% (SPY −0.4%, XLV +15.5%). 1 year: −47.1% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: RARE, SPY and XLV · as of 4 Nov 2026
20.1M shares were sold short at the 15 Oct 2026 settlement, 20.4% of the 98.6M shares outstanding; covering them would take 5.2 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
The 4 Nov 2026 close of $17.16 was 4.3% above its 50-day average ($16.45) and 24.7% below its 200-day average ($22.80). It has closed below the 200-day for 44 sessions, since 3 Sep 2026. The 50-day average crossed below the 200-day on 16 Sep 2026, 35 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Closed at $17.16 on 4 Nov 2026: 57.0% below the 52-week high of $39.89 (8 Dec 2025) and 34.8% above the low of $12.73 (16 Sep 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
4 Nov 2026 volume of 7.5M shares was 2.0× the average of the 30 sessions before it (3.8M), as the price rose 3.2%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
September 3, 2026
−44.03%December 29, 2025
−42.32%July 10, 2025
−25.11%